Trial Profile
A Phase 2 Study of AZD0530 in Patients With Advanced, Recurrent Non-Small Cell Lung Cancer Who Have Previously Received Platinum-Based Combination Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Saracatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 11 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 24 Jul 2009 Planned end date changed from 1 Jan 2009 to 1 Aug 2009 as reported by ClinicalTrials.gov.
- 04 Apr 2008 New trial record.